The ARPA-H ibogaine awards do not mean ibogaine is approved or authorized as a treatment for post-traumatic stress disorder (PTSD). The Advanced Research Projects Agency for Health (ARPA-H), an agency within the Department of Health and Human Services (HHS), says its November 12, 2026 awards fund data and drug-product work for potential future Investigational New Drug (IND) applications. Federal regulation lists ibogaine in Schedule I, and Food and Drug Administration (FDA) approval of ibogaine is not reported in the agency, regulation, state-agency, funding-notice, and sponsor sources reviewed.
The scope is the announced federal awards, related research notices, federal scheduling, and the Texas Health and Human Services Commission's published account. All sources were read on November 14, 2026.
Did the HHS and ARPA-H Ibogaine Awards Make Ibogaine Approved or Legal?
The awards did not change ibogaine's approval or federal scheduling status in the sources reviewed on November 14, 2026. ARPA-H, an agency within the Department of Health and Human Services (HHS), describes work toward potential IND applications. Its November 12 announcement does not describe an FDA approval or a newly authorized PTSD treatment.
FDA approval of ibogaine is not reported in the sources reviewed on November 14, 2026. An IND serves a different purpose: ARPA-H says its teams will produce the data and experimental drug products needed to support future applications for clinical research. ARPA-H also says no current IND exists to conduct clinical research on ibogaine as a psychiatric treatment in the United States. That statement concerns psychiatric research on ibogaine as of November 12, 2026.
Federal scheduling is a separate question. Title 21 of the Code of Federal Regulations, section 1308.11(d)(21), lists ibogaine in Schedule I in the sources reviewed on November 14, 2026. The ARPA-H announcement reports research awards. It does not report a change to that listing. ARPA-H cites President Trump's Executive Order 14401 as the policy context, which the site's executive order guide covers.
A state development effort also differs from federal approval. The Texas Health and Human Services Commission (HHSC) says it selected UTHealth Houston as the lead institution for work under Senate Bill 2308. HHSC says recent plans submitted to it do not meet specified requirements concerning matching state funds and rights-related revenue. HHSC reports no trial start date on its page, as reviewed on November 14, 2026.
What the Awards Fund and What They Do Not Authorize
| Item | Status in the sources reviewed on November 14, 2026 | Source |
|---|---|---|
| ARPA-H awards to Beond and Cost Plus Drug Company | ARPA-H selected both teams for data and drug-product groundwork. Its commitment is up to $4.9 million over five years. | ARPA-H announcement |
| IND for psychiatric clinical research on ibogaine | ARPA-H said on November 12, 2026, that no current IND existed for this specific research purpose. | ARPA-H announcement |
| FDA approval of ibogaine | Not reported in the sources reviewed. The awards do not constitute an approval. | ARPA-H announcement and FDA research notice |
| Federal scheduling | Ibogaine is listed in Schedule I at 21 CFR 1308.11(d)(21). | 21 CFR 1308.11(d)(21) |
| Texas state consortium | The Texas Health and Human Services Commission selected UTHealth Houston as lead institution and reports that recent plans do not meet specified state-law requirements. A trial start date is not reported in the sources reviewed. | Texas HHSC, Ibogaine Clinical Trials page |
| ASCENT-IBO for opioid use disorder | ARPA-H says it is evaluating proposals for this related research effort. An open trial under the effort is not reported in the sources reviewed. | ARPA-H announcement and ASCENT-IBO program page |
| NIMH RAPIDs notice | The separate rapid-acting psychotropics funding announcement does not mention ibogaine. | NIMH RFA-MH-27-150 listing |
| Beond's 250-patient dataset | Beond says it will provide a de-identified dataset from 250 patients. ARPA-H's announcement does not report that figure. | Beond's own page |
What ARPA-H Awarded for Ibogaine Research
ARPA-H selected two teams to prepare different parts of a potential ibogaine research program. Its November 12, 2026 announcement puts the agency's commitment at up to $4.9 million over five years. ARPA-H says funding varies by awardee and depends on each team meeting research milestones.
ARPA-H says Beond, Inc. will deliver clinical data for evaluating ibogaine. The agency assigns Mark Cuban Cost Plus Drug Company, PBC a different job: establishing a regulatory, clinical, chemical, and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product for potential PTSD treatment. Those descriptions identify the work awarded. They do not report a completed clinical trial or an approved product.
ARPA-H frames the psychiatric interest cautiously. Its announcement calls reports of rapid symptom relief from international clinics anecdotal. The agency also points to challenges facing U.S. veterans and cites Executive Order 14401 as context for the work. The site's veterans and psychedelic therapy guide covers that broader policy context without treating anecdotal reports as a clinical finding.
The announcement gives no date for a psychiatric ibogaine trial to open. ARPA-H's stated award deliverables are data and drug-product groundwork for possible future IND applications.
Why the Awards Do Not Open an Ibogaine Clinical Trial
ARPA-H's psychiatric awards prepare material for possible IND applications. The agency does not describe them as an open ibogaine clinical trial. On November 12, 2026, ARPA-H said no current IND existed to legally and safely conduct clinical research on ibogaine as a treatment for psychiatric conditions in the United States. The agency's wording is specific to that compound, purpose, and date.
That wording must not be extended to every related drug or research purpose. In an October 5, 2026 release, the FDA said it had allowed an early-phase study of noribogaine hydrochloride, a derivative of ibogaine, to proceed under an IND for potential treatment of alcohol use disorder. The FDA statement describes noribogaine research. It does not turn ARPA-H's psychiatric ibogaine awards into an open trial.
ARPA-H also describes a related effort called Accelerating Safe Clinical Evaluation of Novel Treatments: Ibogaine for Better Outcomes in Opioid Use Disorder (ASCENT-IBO). Its announcement says the agency is evaluating proposals for that effort. The ASCENT-IBO program page, read on November 14, 2026, says no active clinical trials with the required federal authorization currently exist to rigorously study ibogaine for opioid use disorder in the United States. Neither agency statement supplies an enrollment date for ASCENT-IBO.
The FDA's October 2026 research notice requests information about approaches to early-phase trials of ibogaine drug products. It gives November 20, 2026 as the comment deadline. The FDA says HHS is prioritizing adults with opioid use disorder and adults with PTSD for federally supported research. That priority is not an announcement that a trial is open. The Texas HHSC page likewise describes work toward approval to conduct drug-development trials and reports no start date. For the distinction between research announcements and current legal status, see where ibogaine is legal.
What Beond Says About Its Ibogaine Data
Beond says it will provide ARPA-H with a de-identified dataset from 250 patients treated at its facility in Cancun, Mexico. According to Beond's own page, the dataset includes heart-monitoring records, adverse-event records, and changes in symptoms. Beond operates a paid treatment program, so these are statements by a performer with a commercial interest. ARPA-H names Beond as a data provider but does not give the 250-patient figure in its announcement.
Beond says ARPA-H, its research collaborators, and the FDA will make the analyses and conclusions rather than Beond. That describes Beond's stated plan. Findings from that work are not reported in the sources reviewed on November 14, 2026. Beond's account of the HHS event also says the awards fund development groundwork rather than patient treatment or human-subject research. ARPA-H independently describes its awards as preparation for future IND applications.
Beond's page quotes its cardiologist describing heart-rhythm risk as a serious concern with ibogaine. That is a sponsor statement. The ARPA-H announcement reviewed contains no cardiac statement. The site's ibogaine guide discusses cardiac safety separately. Beond's dataset announcement does not establish that ibogaine is safe or effective for PTSD.
The Separate NIMH Rapid-Acting Psychotropics Notice
NIMH posted a separate funding notice on November 12, 2026 for a Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) Clinical Trials Network. Its full announcement does not mention ibogaine. The notice should therefore not be counted as another ibogaine award in the sources reviewed on November 14, 2026.
The funding listing gives a June 10, 2027 closing date, expected project funding of $12,000,000, and three expected awards. The full announcement separately says NIMH intends to commit up to $10 million and the National Institute on Drug Abuse (NIDA) intends to commit up to $2 million under the terms it describes. Those are the notice's stated figures. The listing and announcement address a different program from ARPA-H's two selected ibogaine performers.
The NIMH announcement defines RAPIDs as pharmacologic interventions that include approved treatments and emerging late-stage investigational treatments. Its examples include ketamine or esketamine, psilocybin, and 3,4-methylenedioxymethamphetamine (MDMA). The announcement says esketamine is currently the only FDA-approved RAPID for mental illness. None of those descriptions names ibogaine as a treatment funded by this notice.
Verdict on the ARPA-H Ibogaine Awards
For a reader asking whether the HHS and ARPA-H awards make ibogaine an approved or authorized PTSD treatment, the answer is no in the sources reviewed on November 14, 2026. ARPA-H's November 12 announcement describes groundwork for future IND applications. FDA approval of ibogaine is not reported in the reviewed sources, and 21 CFR 1308.11(d)(21) lists ibogaine in Schedule I.
This answer applies to the announced federal awards and the status described in the cited agency, regulation, state-agency, funding, and sponsor statements. Nothing here recommends obtaining or using ibogaine. Anyone seeking treatment options should discuss approved options with a clinician. An active IND for the relevant research, an FDA approval, a federal scheduling action, or a substantive Texas HHSC program update would require a fresh assessment of the corresponding status.
Read ARPA-H's dated announcement for research updates, then check the state-by-state legal status map for current state status.